Development asset linked to Helvetic Biopharma in public FDA and regional records.
pharma
Helvetic Biopharma
Helsinn Birex Pharmaceuticals
Helvetic Biopharma drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Dublin, CH HQ
2011 Founded
7 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Dublin, CH
- Founded
- 2011
- Employees
- 7
- Programs
- 1
- Drugs
- 10
- Patents
- 0
Helvetic Biopharma pipeline
Portfolio lens on 10 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Helvetic Biopharma drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Helvetic Biopharma in public FDA and regional records.
-
Development asset linked to Helvetic Biopharma in public FDA and regional records.
-
Development asset linked to Helvetic Biopharma in public FDA and regional records.
-
netupitant
Alimentary tract and metabolism (A04)US regulatory status: approved. Molecular target: Substance-P receptor.
- Target
- Substance-P receptor
- Mechanism
- Neurokinin 1 receptor antagonist
-
Development asset linked to Helvetic Biopharma in public FDA and regional records.
-
palonosetron
Alimentary tract and metabolism (A04)Alimentary tract and metabolism (A04) compound in Helvetic Biopharma's portfolio. Mechanism: Serotonin 3a (5-HT3a) receptor antagonist.
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist
-
Development asset linked to Helvetic Biopharma in public FDA and regional records.
-
Development asset linked to Helvetic Biopharma in public FDA and regional records.
-
Development asset linked to Helvetic Biopharma in public FDA and regional records.